Resverlogix Corp.

Senior Management

Donald J. McCaffrey

President and CEO, Co-Founder

Don is Resverlogix’s strategic leader, founder, mentor and the overall ‘heart’ of the company.


Donald McCaffrey is Co-Founder, President, & CEO of Resverlogix Corp. He has over 30 years of experience in drug discovery & development, and international conference and tradeshow management across multiple industries, including biotechnology. Don has led Resverlogix through significant change and achievement from its initial days as a private company to becoming a TSX listed company, including raising over $185 million.  In addition to garnering appropriate financing for Resverlogix’s aggressive development plan, Don has strategically directed the Company in its discussions with top global pharmaceutical companies, while creating new therapeutic markets for its key technology platforms. Don’s expertise in corporate operations has attracted an international team of R&D experts to Resverlogix.  This scientific and operational expertise has pioneered RVX-208, a drug which has the potential to be first in a new class of drugs for the treatment of cardiovascular disease.  Under his guidance Resverlogix has won multiple awards including the 2008 WEF Technology Pioneer award.

Don’s career accomplishments have been recognized by the business community and peers, as he was nominated for Ernst & Young Entrepreneur of the Year twice. He is a contributor to community non-profit organizations including the United Way, Mount Royal College, Alberta Children's Hospital, Education Matters, and Calgary Urban Project Society Literacy Program.

Dr. Norman C.W. Wong, M.D., FRCP

Chief Scientific Officer & Co-Founder

Norman is the visionary for the scientific development of Resverlogix’s therapeutic platforms.


Dr. Wong's research interest focus is on the molecular actions of hormones related to the regulation of lipoprotein expression and pathogenesis of diabetes mellitus. His clinical interest encompasses patients with thyroid disease or diabetes mellitus. His most recent successes have come from elucidating the potential therapeutic opportunities for cardiovascular disease by harnessing the regulation of Apolipoprotein A-I (ApoA-I) gene expression.

Dr. Wong keeps active in the academic community with speaking engagements at national and international medical conferences. He has been the author and co-author of more than 275 articles and abstracts and has been invited to sit on more than 40 national or international panels and committees. He has also acted as a consultant to several leading pharmaceutical companies, including Eli Lilly, Merck Frost, GlaxoSmithKline, Solvay Pharmaceuticals and Abbott Laboratories.

A. Brad Cann, CA

Chief Financial Officer

Brad is responsible for accounting, taxation, finance, treasury, corporate governance and risk management.


Brad has more than 14 years of financial and business experience. Prior to joining Resverlogix, Brad was Executive Vice President and Chief Financial Officer of Royal Host Real Estate Investment Trust, a diversified hospitality trust engaged in hotel ownership, investment, management and franchising, and Canada's second largest hotel REIT. Brad joined Royal Host in January 2004 and held a number of senior positions and was appointed Chief Financial Officer in May 2007 and Executive Vice President in January 2008. Brad's responsibilities included financial reporting, accounting, taxation, investor relations, payroll, information technology and internal audit. As acting Co-Chief Executive Officer of Royal Host, Brad shared responsibility for developing the strategic initiatives of the Trust and leading its executive team in day-to-day operations, as well as investing, financing and real estate transactions. 

Prior to joining Royal Host, Brad was a business consultant and held senior management positions with several companies including Chief Financial Officer of a sulphur export development company and Chief Financial Officer of an oilfield waste water treatment company. Prior thereto, Brad held various positions with a chartered accounting firm.

Brad is a Chartered Accountant and a Chartered Business Valuator, and holds a Bachelor of Commerce from the University of Saskatchewan.

Dr. Jan O. Johansson, M.D., Ph.D.

Senior Vice President Medical Affairs

Jan oversees the clinical and regulatory development, and provides scientific guidance to the corporation.


Dr. Johansson has had a distinguished 30 plus year career of which the past 18 years have been in small biotechnology and large pharmaceutical companies with expertise in the cardiovascular disease therapeutic area. He has served as Chief Medical Officer at Nuvelo, Inc., VP, Clinical Research and Development at Lipid Sciences, Inc. and was Co-founder, VP, Clinical Affairs and Senior Clinical Research Fellow of Esperion Therapeutics, Inc. From 1995 to 1997, Dr. Johansson was a medical adviser with executive responsibilities at Pharmacia bringing one lipid lowering product to the market and heading the apolipoproteinA-IMilano clinical program.

Dr. Johansson earned his M.D. and Ph.D. at the Karolinska Institute in Sweden where he lead a successful career as a tenured associate professor at the Karolinska Hospital and as a practicing physician. He has published more than 50 peer-review medical articles, and is a member of several scientific organizations including the American Heart Association and the European Atherosclerosis Society.

Dr. Michael Sweeney, M.D.

Senior Vice President of Clinical Development

Mike will oversee clinical development programs for RVX-208 in cardiovascular disease (CVD), Diabetes Mellitus, and other indications.


Dr. Sweeney, a cardiologist with extensive experience in pharmaceutical product development and marketing, will oversee clinical development programs for RVX-208 in cardiovascular disease (CVD), diabetes mellitus, and other indications.

Dr. Sweeney has an impressive career history, spanning over 26 years in the pharmaceutical industry. This includes 11 years at Pfizer Inc., holding a variety of senior-level medical and marketing positions, including Senior Director, Urology Global Medical Group Leader and Director of Marketing of the Viagra® Worldwide Team. Prior to joining Resverlogix, Dr. Sweeney was Chief Medical Officer and Vice President of Research and Development at Depomed, Inc. in Silicon Valley. Dr. Sweeney was also the Vice President of Medical Affairs at CV Therapeutics, Inc., where he built the medical affairs department to enable the successful launch of Ranexa® for patients with cardiovascular disease and chronic angina.

Dr. Sweeney holds biochemistry and medical degrees from Liverpool University and an advanced medical research degree from Manchester University in the U.K. Dr. Sweeney also holds post-graduate diplomas in pharmaceutical medicine and pharmaco-epidemiology from the University of London. He is a fellow of the Royal College of Physicians of Edinburgh.

Kenneth Lebioda, BA

Senior Vice President Business & Corporate Development

Ken is responsible for the business and corporate development of the company’s technology pipeline and alliance management.


Ken has over 25 years experience in the innovative pharmaceutical industry with leading global companies such as Bristol-Myers Squibb, Hoechst Marion Roussel and Marion Merrell Dow. He held a variety of management positions with these companies in the areas of sales and business development, regulatory affairs, reimbursement and market access. Ken's past contributions in helping build leading global cardiovascular brands such as Plavix, Pravachol, Cardizem, and Avapro will provide strategic guidance for the company's technologies in the areas of market analysis, regulatory affairs, pharmacoeconomics, licensing and commercial development.

Dr. Henrik C. Hansen, Ph.D.

Vice President of Intellectual Property & Technology Development

Henrik is responsible for the intellectual property portfolio and for integration of the corporate, scientific, business and financial objectives.


Henrik C. Hansen joined Resverlogix in 2005 and currently holds the position of VP of Intellectual Property & Technology Development.  Henrik is responsible for the intellectual property portfolios at Resverlogix, and he assumes a leading role in the implementation of corporate objectives by interfacing with all parts of the corporation; monitors resource needs and ensures that appropriate resources are available and aligned with corporate goals. He provides insight to achieve the right balance between science, business, and financial objectives, by applying a strong understanding of all aspects of the corporation.

Henrik has more than 13 years of experience, from both academia and industry, in basic research, drug discovery, and drug development. His areas of expertise include medicinal chemistry and carbohydrate chemistry, process development, and manufacturing of drug substances and drug products under cGMP for clinical use.

Henrik holds a M.Sc. in Chemical Engineering from the Technical University of Denmark and a Ph.D. in Organic Chemistry from Lund University, Sweden. He has authored or co-authored more than 40 articles and meeting abstracts and is listed as inventor of 9 patent families.